Publication date: Nov 15, 2024
Therapies beyond antibiotics such as vaccines and monoclonal antibodies have emerged as promising, preventative strategies for sepsis due to tuberculosis and anti-microbial resistant infections. LHNVD-303 is designed to prevent bacterial infections, and clear associated toxins, including those related to Mycobacterium tuberculosis, using a targeted combination of lipoteichoic acid, lipopolysaccharide and peptidoglycan. Peptide-based vaccines such as LHNVD-303 and the corresponding monoclonal antibodies have shown promise for active and passive immunization as well as treatment, providing a strategy that synergizes with antibiotics. Multi-drug resistant bacterial pathogens such as Mycobacterium tuberculosis are a global threat to human and animal health.
| Concepts | Keywords |
|---|---|
| Antibiotics | Bacterial |
| Longhorns | Composite |
| Organ | Diagnostic |
| Zoonosis | Diagnostics |
| Global | |
| Lhnvd | |
| Longhorn | |
| Mycobacterium | |
| Peptide | |
| Prevent | |
| Resistant | |
| Sepsis | |
| Tuberculosis | |
| Vaccine | |
| Vaccines |
Semantics
| Type | Source | Name |
|---|---|---|
| pathway | REACTOME | Infectious disease |
| disease | MESH | infectious disease |
| disease | IDO | role |
| drug | DRUGBANK | Coenzyme M |
| disease | IDO | infection |
| disease | IDO | bacteria |
| disease | MESH | infections |
| disease | MESH | death |
| disease | MESH | causes |
| disease | MESH | bacterial infections |
| disease | IDO | zoonosis |
| disease | MESH | Tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | MESH | Sepsis |
| disease | MESH | Influenza |